Overview

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Axitinib